Goodwin Procter advised Avadel Pharmaceutics on the deal. Avadel announced its royalty agreement with RTW Investments, LP and certain of its affiliates for up to $75 million....
Avadel Pharmaceuticals’ $75 Million Royalty Financing
Bicara Therapeutics’ $108 Million Series B Financing
Goodwin Procter advised Bicara Therapeutics on the deal. Bicara Therapeutics announced the completion of its oversubscribed $108 million Series B financing to advance the company’s lead program...
Royalty Pharma’s Acquisition of Royalty Interest in TRELEGY ELLIPTA
Goodwin advised Royalty Pharma plc on the deal. Royalty Pharma plc (Nasdaq: RPRX) announced its definitive agreement to acquire a royalty interest in TRELEGY ELLIPTA (Trelegy) from...
Royalty Pharma’s Acquisition of Theravance Respiratory Company
Skadden advised Theravance Biopharma, while Goodwin Procter advised Royalty Pharma on the deal. Willkie Farr & Gallagher advised Innoviva on the sale of its stake in...
HIBio’s License Agreements with MorphoSys AG
Goodwin Procter advised HIBio on the deal while Orrick represented MorphoSys. HIBio announced its equity participation agreement and license agreements with MorphoSys AG (FSE: MOR; NASDAQ: MOR)....
Garuda Therapeutics’ Launch and $72 Million Series A Financing
Goodwin Procter advised Garuda Therapeutics on the deal. Garuda Therapeutics announced its launch and $72 million Series A financing led by Aisling Capital, Northpond Ventures, and OrbiMed,...